Total Payments
$23,592
2019 Payments
$17,519
Companies
4
Transactions
37
Payment Breakdown by Category
Consulting$18,200 (77.1%)
Travel$3,272 (13.9%)
Research$1,170 (5.0%)
Food & Beverage$949.61 (4.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $18,200 | 3 | 77.1% |
| Travel and Lodging | $3,272 | 13 | 13.9% |
| Unspecified | $1,170 | 13 | 5.0% |
| Food and Beverage | $949.61 | 8 | 4.0% |
Payments by Type
General
$22,421
24 transactions
Research
$1,170
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Acorda Therapeutics, Inc | $9,813 | 7 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $7,706 | 9 | $0 (2019) |
| Relypsa, Inc. | $4,902 | 8 | $0 (2017) |
| SANOFI US SERVICES INC. | $1,170 | 13 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $17,519 | 16 | Acorda Therapeutics, Inc ($9,813) |
| 2018 | $1,170 | 13 | SANOFI US SERVICES INC. ($1,170) |
| 2017 | $4,902 | 8 | Relypsa, Inc. ($4,902) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/17/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 08/06/2019 | Acorda Therapeutics, Inc | — | Consulting Fee | Cash or cash equivalent | $8,550.00 | General |
| 07/26/2019 | Acorda Therapeutics, Inc | — | Food and Beverage | Cash or cash equivalent | $238.24 | General |
| 07/26/2019 | Acorda Therapeutics, Inc | — | Travel and Lodging | Cash or cash equivalent | $103.56 | General |
| 07/25/2019 | Acorda Therapeutics, Inc | — | Travel and Lodging | Cash or cash equivalent | $344.60 | General |
| 07/25/2019 | Acorda Therapeutics, Inc | — | Travel and Lodging | Cash or cash equivalent | $239.57 | General |
| 07/25/2019 | Acorda Therapeutics, Inc | — | Food and Beverage | Cash or cash equivalent | $239.57 | General |
| 07/25/2019 | Acorda Therapeutics, Inc | — | Travel and Lodging | Cash or cash equivalent | $97.44 | General |
| 05/29/2019 | Merck Sharp & Dohme Corporation | MK-1242 (Drug) | Consulting Fee | Cash or cash equivalent | $6,500.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/29/2019 | Merck Sharp & Dohme Corporation | MK-1242 (Drug) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/03/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $108.07 | General |
| 05/03/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 05/03/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $49.98 | General |
| 05/03/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $33.96 | General |
| 05/02/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $532.60 | General |
| 05/02/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $246.28 | General |
| 09/28/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $60.44 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/28/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/28/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | Cash or cash equivalent | $35.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/28/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | Cash or cash equivalent | $32.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/28/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $29.81 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/28/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | Cash or cash equivalent | $16.12 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/27/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $333.68 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/27/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $239.05 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/27/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $186.66 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | SANOFI US SERVICES INC. | $1,170 | 13 |
About Dr. Flora Sam, M.D
Dr. Flora Sam, M.D is a Cardiovascular Disease healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316918337.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Flora Sam, M.D has received a total of $23,592 in payments from pharmaceutical and medical device companies, with $17,519 received in 2019. These payments were reported across 37 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($18,200).
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Boston, MA
- Active Since 01/28/2006
- Last Updated 06/13/2014
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1316918337
Products in Payments
- MK-1242 (Drug) $6,650
- Veltassa (Drug) $4,902
- SAR439954 (Drug) $1,170
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Boston
Dr. Elizabeth Nabel, M.d, M.D
Cardiovascular Disease — Payments: $3.0M
Cardiovascular Disease $3.0M
Kenneth Rosenfield, M.d, M.D
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Eric Secemsky, Md, Msc, MD, MSC
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Benjamin Scirica, M.d, M.D
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Jorge Plutzky, Md, MD
Cardiovascular Disease — Payments: $973,823
Cardiovascular Disease $973,823
Christopher Cannon, Md, MD
Cardiovascular Disease — Payments: $869,405
Cardiovascular Disease $869,405